Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose Buprenorphine as a Modulator of Social Motivation in Schizophrenia
NCT05778591Phase 2Recruiting
- Sponsor
- University of California, Los Angeles
- Start
- May 2024
- Primary completion
- Dec 2026
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of buprenorphine in schizophrenia, sponsored by University of California, Los Angeles. Started May 2024; status: recruiting.
02
Drugs
buprenorphine
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT05778591.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05778591.